Table 1.
Therapeutic spectrum of compound 1 against HIV-1 Subtypes.
| HIV-1 isolate | Compound | IC50 (μM) | Antiviral index† (TC50/IC50) |
|---|---|---|---|
| 92UG031 Subtype A |
MTI535 | 17.8 (±2.6) | > 5.6 |
| 89BZ167 Subtype B |
MTI535 | 17.7 (±2.9) | > 5.7 |
| 92BR030 Subtype B |
MTI535 | 20.3 (±2.9) | > 4.9 |
| 92BR025 Subtype C |
MTI535 | 16.3 (±4.3) | > 6.1 |
| 93IN101 Subtype C |
MTI535 | 16.3 (±4.2) | > 6.1 |
| 92UG024 Subtype D |
MTI535 | 16.0 (±7.8) | > 6.25 |
| CMU08 Subtype E |
MTI535 | 17.7 (±4.8) | > 5.7 |
| 93BR020 Subtype F |
MTI535 | 17.3 (±4.8) | > 5.8 |
| G3 Subtype G |
MTI535 | 18.9 (±2.9) | > 5.3 |
| BaL Subtype B |
MTI535 | 27.8 (± 5.0) | > 3.6 |
| NL4-3 Subtype B |
MTI535 | 30.8 (± 0.9) | > 3.3 |
| MDR769 Subtype B |
MTI535 | 18.8 (± 3.3) | > 5.3 |
†
TC50 values for all compounds were determined to be >100 μM in this study. Numbers in parentheses represent one standard deviation derived from three replicate assays.